BioPlus releases updated version of hepatitis C treatment app

BioPlus Specialty Pharmacy, a pioneer in innovative pharmaceutical care, on Tuesday announced the release of an updated version of the HCV Treatment Path app.

The app helps keep healthcare providers up to date on the latest treatment guideline for chronic hepatitis C virus infection, while complying with treatment guidelines from credible, scientific sources.

“Our goal, with the HCV Treatment Path app, continues to be getting the latest treatment protocols to providers,” BioPlus Chief Operations Officer Elvin Montanez said. “The providers already using this app rely on it in the decision-making process; we’ve received amazing feedback about the app from providers who appreciate the simplicity of accessing information they can trust. This updated version was necessary to continue putting the most relevant tool into providers’ hands.”

Hepatitis C treatment has undergone fast evolution, in light of numerous newly approved medications and an developing understanding of how each medication is best suited for different patient classes.

“For example, the AASLD has made recent changes to recommendations for treatment naïve and treatment experienced patients, including new recommendations for patients who have tried and failed the medications Sovaldi, Harvoni, or Viekira,” BioPlus Clinical Pharmacy Specialist Monica Morgan said. “With the HCV Treatment Path app, providers can quickly view the most up-to-date recommendations to assist them in making decisions about which treatment option is best for each patient.”